# UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners Standard Operating Procedure (LocSSIPs)

<table>
<thead>
<tr>
<th>APPROVERS</th>
<th>POSITION</th>
<th>NAME</th>
</tr>
</thead>
</table>
| Person Responsible for Procedure: | Consultant Ophthalmologist | Ms Rossella Anzidei  
Mr Vasileios Konidaris |
| SOP Owner: | General Manager | Zack Senta |
| Sub-group Lead: | Clinical Director MSS | Andy Curry |

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Summary
This policy describes the processes required for non-medical healthcare professionals to carry out intravitreal injections of anti-VEGF medication.

1. Introduction
In recent years, the injection of drugs into the vitreous has expanded rapidly to become hugely important in the treatment of medical retinal diseases and the commonest ophthalmic procedure performed. Most intravitreal injections are to deliver anti-vascular endothelial growth factor medications (anti-VEGF) or steroid drugs and implants. These intravitreal drugs include Avastin (bevacizumab), Lucentis (ranibizumab), Eylea (aflibercept) for patients with age related macular degeneration (AMD), diabetic macular oedema (DMO), retinal vein occlusion (RVO) and other macular disorders. Steroids include triamcinolone and dexamethasone and implants include Ozurdex (dexamethasone) and Iluvien (fluocinolone) used to treat DMO, RVO and uveitis. These treatments are governed by NICE guidelines and require repeated timely follow up and treatment. As a consequence, attendances within the eye clinics have increased significantly and put significant demands on the available capacity. The involvement of non-medical healthcare professionals (HCP) in assessing patients and/or performing intravitreal injections has become widely accepted practice to cope with this demand and to support the expansion of non-medical roles, and is supported by the Royal College of Ophthalmologists.

2. Purpose
This policy sets out the process required for designated HCP to train and to deliver intravitreal injections as independent non-medical injectors to the standards required by NICE and the Royal College of Ophthalmologists. This will contribute to the efficient delivery of the medical retinal service and will enhance and develop patient-centred care which fulfils national safety and service delivery targets. Service provision will be more flexible and resilient, with the potential for increased capacity for treatment. Staff will be able to develop their roles further, increasing the overall level of expertise in the department and promoting greater job satisfaction.

The policy provides details of:

- the training and competencies
- guidance for the management of patients
- standard operating procedures
- the process to be used for monitoring compliance with the process and outcomes.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
This document should be read in conjunction with the joint Colleges’ Ophthalmic Common Clinical Competency Framework (OCCCF). https://www.rcophth.ac.uk/professional-resources/new-common-clinical-competency-framework-to-standardise-competences-for-ophthalmic-non-medical-healthcare-professionals/

3. Scope
This policy applies to all trust sites where intravitreal injections are carried out and is relevant to non-medical practitioners, ophthalmic nurses, orthoptists and optometrists who are or wish to become injectors, to ophthalmologists in the adult medical retina service and to those managing ophthalmology retinal services.

It should be read in conjunction with other relevant trust documents:
- Infection Control Policy
- Medicines Management Policy
- Consent Policy
- Clinical Governance/Risk Management Policy.

4.0 Duties and responsibilities
4.1 Practitioners responsibilities
Practitioners undertaking the training are responsible for compliance with trust policies; engaging actively with the training, keeping up to date, accurate training records; ensuring they act within their sphere of competence; completing accurately the relevant parts of the medical records; following SOPs; reporting adverse events and safety concerns to their supervisor, consultant or their line manager.

Practitioners are accountable for their own practice and must adhere to their relevant Professional Body and Regulatory Body requirements, guidelines and codes of practice / conduct.
Failure to do so could result in the loss of protection from the trust’s liability cover and individual professional indemnity cover, could result in investigation and formal action in line with disciplinary procedures and may put the practitioner’s registration at risk if concerns are raised about fitness to practice.

Once signed off as competent to practice independently, the HCP is required to audit their patient records after the first 6 months or first 100 cases and then yearly as part of their annual appraisal / individual performance review.
HCPs must attend a mandatory annual peer review and clinical update session on intravitreal injections.

### 4.2 Consultant ophthalmologist’s and trainer’s responsibilities

The consultants must ensure the HCP has achieved a satisfactory knowledge base and competencies with which to perform this enhanced role. The consultant can undertake this directly or can delegate some or all parts to a senior colleague with appropriate experience, knowledge and training who is a named intravitreal injection trainer that is an HCP with more than 2 years’ independent intravitreal injection experience, or a fellow or ST 6 and above ophthalmic trainee. However, the consultants retain responsibility for the training and sign off before the HCP begins independent practice.

The trainer will:

- Formally examine the HCP to ensure she/he has the knowledge base required
- Ensure the HCP only progresses to each stage of training once they are sure that prior training is complete/competency has been achieved and the practitioner is ready to progress.
- Provide adequate time for the HCP to observe intravitreal injection technique and to subsequently supervise and assess the HCP’s procedural skills.

The consultant will arrange that they or a suitably other ophthalmologist is immediately available to support the HCP during an intravitreal injection clinic. The doctor should either be present in the clinical area or, if the HCP is competent to manage immediate emergencies (see below), by phone with a pathway in place to see a doctor urgently with the appropriate safe timescale if required, once the HCP has undertaken initial treatment.

The patient remains under the care of a named consultant ophthalmologist at all times.

### 4.3 Managers responsibility

The manager(s) [lead nurse, lead orthoptist, lead optometrist or ophthalmology department manager] will keep a record of all competencies and a register or list of named trainers and HCPs eligible to perform independent injecting.

Managers must only endorse skills if such development is in line with the practitioner’s job description and existing trust policies and service requirements.

Managers must ensure that the practitioner is supported in skills development in the form of:

- Opportunities for supervised practice
- Assessment of competency and sign off.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)
4.4 Employer’s responsibilities
The employer will ensure that the HCP’s training and supervision is provided in a timely manner, ensuring trainers and supervisors are supported to deliver the time required. Employers will ensure HCPs are appropriately banded for the work they undertake and are given the time to undertake the training and audit during their current role.
The employers will ensure that, subject to following trust policy, HCPs have suitable indemnity for this scope of practice.

5.0 Training (see appendix 1)
HCPs can only commence training after identification as suitable by the Lead Nurse and approval by their line manager. Training will be carried out as detailed in appendix 1. Practitioners will receive theoretical training initially and, when completed, will undertake observational training and, when this is completed, will undertake practice supervised by a consultant or nominated trainer. At each stage, the practitioner can proceed to the next stage of training only if their trainer considers he/she is ready. They will require assessment as competent by their trainer and competencies recorded as detailed in appendix 2 and have undertaken and evidenced reflective practice. The practitioner must be satisfied with his/her own level of competence in accordance with the guidelines and codes of conduct from their relevant regulator and professional body.
The HCP will undergo an informal review of practice with their trainer and/or the medical retinal consultant and/or lead nurse after three months of independent injecting.

6 Frequency of practice
HCP led intravitreal injection clinics will be carried out according to service need. Once a practitioner has been signed off as competent, they should be performing injections regularly to maintain skills. In injection only clinics (not one stop) usually no more than 15 injections should be carried out per morning/afternoon session unless there are exceptional circumstances such as an increased number of bilateral cases. Additional patients can only be added to each list with the confirmed agreement of the HCP and the consultant/senior doctor in charge of the session. HCPs will be expected to deliver a maximum number of three sessions per week and will only exceed this number with their express agreement.

7. Outcome measures
Data to be collected is:
- Record of all cases to be kept by HCPs for activity levels
- Data capture/audit.
Post-operative endophthalmitis level comparable to doctor endophthalmitis level and in line with RCOphth guidance and evidence from literature. Any cases identified need to be reported as incidents and medical retina consultants should undertake with managers and inflectional control team a root cause analysis (RCA) investigation.

- Number of cases presenting as emergencies post injection comparable to rates experienced by medical practitioners and within normal limits.
- Any incidents or serious incidents or patient complaints, including the result for the patient or of any investigation, with appropriate reflective practice and learning recorded
- Patient experience / satisfaction survey at discretion of HCP and line manager.

The HCP will undertake an audit of their first 100 cases or first 6 months practice, and on an annual basis thereafter as part of their annual appraisal and individual performance review.

8.0 Approval and ratification
This policy was approved by the Ophthalmology Consultants and ratified by the MSS Board.

9.0 Dissemination and implementation
This policy will be implemented and disseminated to all staff involved in the administration of intravitreal injections or medical retinal care, and will be communicated to key stakeholders and policy users via email, and highlighted at team meetings.

This policy will be published on the trust intranet site.

10.0 Review and revision arrangements
This document will be reviewed on a 3 year basis by the Policy Owner/Authors. Changes to the legislation or national guidelines of the administration of intravitreal injections by non-medical personal, or any trust serious incidents will trigger a review of this document.

11.0 Monitoring compliance with this policy
Monitoring compliance will include:

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Element to be Monitored | Staff conducting | Tool for Monitoring | Frequency | Responsible Individual/Group/Committee for review of results/report | Responsible individual/group/committee for acting on recommendations/action plan
--- | --- | --- | --- | --- | ---
Service delivery and unit outcomes | Lead Retinal Consultant | Audit | Every 12 months | Ophthalmic clinical governance/audit meetings | Ophthalmic or MR clinical lead
HCPs | Lead Retinal Consultant and Lead Nurse | Audit and patient satisfaction survey | For the first 100 patients then annually | Lead Consultant and Lead Nurse | Retinal Team
Complications or adverse events to be recorded | All staff | Incident reporting | ongoing | Lead consultants Risk team | Ophthalmology CG
Complaints | Complaints team | Complaints process | ongoing | Lead consultant Ophthalmology manager PALS | Ophthalmology CG

12.0 Supporting References / Evidence Base

National documents
The Health & Care Professions Council (HCPC) Standards of Conduct, performance & ethics http://www.hpcuk.org/aboutregistration/standards/standardsofconductperformanceandethics/
BIOS – Intravitreal therapy standards of practice 2016..

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Royal College of Ophthalmologists (2018) Guidance intravitreal injections
Royal College of Ophthalmologists (2013) College Statement on intra-ocular injections by non-medical health care professionals
http://www.rcophth.ac.uk/news.asp?itemid=1363&itemTitle=College+Statement+on+intraocular+injections+by+non-medical+health+care+professionals&section=24&sectionTitle=News+May+2013
RCOphth Quality Standards for medical retina services. RCOphth 2018.
NICE guidance for AMD. https://www.nice.org.uk/guidance/ng82

**Local documents**
Infection control policy
Ophthalmology department guidelines
Consent policy
Clinical record keeping policy
Clinical governance policy
Risk management policy
WHO checklist/Surgical Safety Policy
Mental capacity policy

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)
Authors: Rossella Anzidei & Vasileios Konidaris
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Appendix 1: Training programme for non-medical clinical professionals administering intravitreal injections

Eligibility: Practitioners must fulfil the requirements of the policy in terms of qualifications and experience and have approval by the Lead Nurse and their line manager before undertaking training. Practitioners must ensure that all training in development is in line with scope of practice and job description and must submit any application for training to their manager for endorsement.

Who can provide training?
Medical retinal consultants can provide training alongside the retinal or ophthalmology Lead Nurse. Part or all of the training can also be provided by the following staff, if approval has been granted by the medical retinal lead consultant or other retinal consultant:

- Consultant injectors
- SAS doctors
- Fellows
- Trainees of ST6 and above
- HCPs with more than 2 years continuous (or equivalent) of independent injecting experience in the NHS.

The training programme
There are two main parts to the training programme, and the practical training comprises 3 aspects:

- Theoretical training
- Practical training
  - Observation of practice
  - Supervised practice:
    - preparation of patient
    - administration of injection

The member of staff must have completed the intravitreal training course including both theoretical and practical components and have been assessed as competent by their supervising consultant or trainer. All training completion must be approved by a medical retinal consultant if it has been delivered by other trainers before independent practice commences.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
1. **Theoretical training**

To be delivered in a number of ways:

- Attendance at a recognised external intravitreal training day e.g. Moorfields course
- Locally delivered half to one day training course run by local medical retinal consultants and non-medical health care professionals.
- One to one sessions with medical retina consultant to informally cover key knowledge.
- Educational DVD or online video training

Topics which must be covered through these routes are as follows:

- Anatomy and physiology of the eye and the retina
- Classification of macular disease
- OCT images (relevant to macular disease)
- Issues around infection control and intravitreal injections
- Pharmacology update (to include all drugs administered during injection visits)
- Risk and legal issues around extended role development
- Latest clinical information on treatment and treatment delivery and up to date evidence underpinning this practice
- How to audit HCP injections
- Consenting for intravitreal injections
- Process of giving intravitreal injection, including the practicalities
- Recognition of complications and what actions to take.

The practitioner needs to undergo an assessment with a trainer to record their knowledge competencies and understanding of key trust policies and national requirements and obtain sign off.

2.1 **Practical Training: Observation of practice**

On satisfactory completion of the theory training, HCPs in training can commence their period of observation whereby they shadow their assigned trainer(s) and follow each patient from assessment through to discharge. Once the treatment of twenty patients has been observed, recorded on the competency assessment log sheet which is countersigned by the trainer, the next stage can begin.
2.2 Practical training: Supervised Practice: Preparation of the patient

The next step of the training pathway is to prepare the patient for the intravitreal injection. The practitioner will need to be able to demonstrate the following:

- Checks room and equipment and drugs including emergency equipment
- Confirmation patient identity
- Suitable assessment key factors and consent in the records
- Checks patient history
- Explanation of the procedure to the patient
- Explanation HCP led procedure
- Checks allergies
- Confirms which eye to be injected
- Positioning of the patient and discussion on comfort
- Hand hygiene
- Skin and eye cleansing
- Insertion of the speculum

On completion of twenty preparations with completion of the signed competency sheet, the trainer will decide if the practitioner can proceed to the next stage or whether further practice is required.

2.3 Practical training: Supervised Practice: Administration of the injection

The final step of the training pathway will be for the practitioner to administer the intravitreal injection. The practitioner will, under strict supervision, administer at least 30-50 injections before the trainer will assess whether the practitioner is safe to proceed independently.

If at this stage the practitioner is not yet ready to practice unsupervised they must continue supervised practice until the trainer feels they are ready for a further assessment. The trainer must also be happy that the practitioner can undertake lists to the required safety and efficiency to practice independently a whole list.

All the competencies must be completed and signed off and audit of practice must occur at this stage and be approved by a medical retinal consultant before undertaking independent practice. In addition, there should be evidence of reflective practice.

At all stages, The HCP trainee must not be signed off as a competent practitioner unless the trainer and consultant are fully confident in the practitioner’s ability to run independent lists.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
The first 3 lists/clinics should occur with experienced injectors nearby with some degree of supervision to ensure support is nearby and practitioners have gained the confidence to practice independently.

After three months, the HCP should undergo a review of their independent practice with a trainer or consultant and should then undertake the required audit after the first 6 months or 100 cases and thereafter every year and regular reflective practice.
Appendix 2. Competencies.

For **New Practitioners** who are undertaking intravitreal injection as a new skill:

You must complete the training and then ensure all competencies signed off not only by your trainer, but also by the medical retina consultant before you practice independently. You must be reassessed against the competency standard every year or after a break of six months of more where the skills have not be undertaken. You must also be confident you are performing within your sphere of competency.

For **Current Practitioners** who have:

- Completed the HCP training programme previously and have been assessed and signed off as competent against the HCP competencies.

You must be assessed as competent using this competency standard by a competent trainer before continuing to undertake the skill independently. You must be reassessed against the competency standard every year or after a break of six months of more where the skills have not be undertaken. You must also be confident you are performing within your sphere of competency.

All practitioners must ensure that successful completion of the competencies occur on time and that this is fully discussed and signed off by the trainer. Practitioners must ensure that copies of the signed competency are sent to their manager, and they should retain a copy for their own portfolio.

**The assessor**

The assessor must be a competent medical injector or HCP who is on the list of approved trainer/assessors. The assessor must only sign the competency when all aspects of the competency standards have been demonstrated by the practitioner.
Competency recording forms

Intravitreal injections: Competency checklist - knowledge

<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th>Assessor’s / Self Assessor’s Signature</th>
</tr>
</thead>
</table>
| 1          | Demonstrate familiarity with and understanding of the principles of the Trust Framework for Enhancing the Scope for Clinical Practice | States key aspects of Trust Framework for Enhancing the Scope for Clinical Practice/Intravitreal injection policy:-  
- Competence to be assessed via Trust ratified competencies.  
- Competency development must be appropriate and safe.  
- Vicarious liability.  
- On-going competency-Trust requirements  
- Evidenced based practice. |
<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 2          | Demonstrate familiarity with Trust Infection Control Policy | **Under observation and where appropriate can state and demonstrate:**  
• Correct use of Personal Protective Equipment.  
• Safe handling of sharps.  
• Safe handling of clinical waste and spillage.  
• Decontamination of equipment.  
• Decontamination of environment.  
**Under observation and where appropriate can state and demonstrate:**  
• The importance of correct hand hygiene. |            |            |
| 3          | Demonstrate familiarity with Trust policy and Profession specific guidelines on records and record keeping | **State and discuss:**  
• The key points in the Trust for Records and Record keeping.  
• The importance of accurate documentation.  
• Individual accountability and confidentiality.  
**Under observation:**  
• Can document the appropriate information accurately and according to Trust Policy in the notes. |            |            |
<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th>Assessor’s / Self Assessor’s Signature</th>
</tr>
</thead>
</table>
| 4 | Demonstrate familiarity with the Trust Consent to Policy | **State and discuss:**  
- The key principles of the Trusts Consent Policy with respect to consenting for care and treatment.  
- Staff responsibility and accountability for ensuring that they act in accordance with the policy when consenting patients for treatment including recognising when they are not permitted to take consent.  
- For consent to be valid, the patient must:  
  o Be competent to take the particular decision;  
  o Have received sufficient information to take it;  
  o Not be acting under duress.  
- Patient’s agreement to the intervention and the discussions which led up to that agreement.  
- Process to follow when a patient does not have capacity to consent and in emergency situations.  
- Process to follow when a patient refuses treatment or changes their mind about consenting to a procedure when they have already signed the consent form  
- Documentation – either through the use of a consent form or through documenting in the patient’s health records that they have given verbal consent. |
### Competency: Uphold the Nursing & Midwifery Council: The Code Professional Standards of practice and behaviour for nurses (2015) or similar professional standards

#### Health Care Professions Council Standards of Conduct, Performance and Ethics

### Competency Checklist

- **State and discuss key aspects of the NMC or similar Code:**
  - Exists to safeguard the health and wellbeing of the public.
  - Sets the standards of education, training and conduct that Nurses and Midwives need to deliver high quality healthcare consistently throughout their careers.
  - Ensures that Nurses and Midwives keep their skills and knowledge up to date and uphold the standards of their professional code.
  - Ensures that Midwives are safe to practise by setting rules for their practice and supervision.
  - Fair processes to investigate allegations made against Nurses and Midwives who may not have followed the code.

- **State and discuss key aspects of the Health Care Professions Council Standards of Conduct, Performance and Ethics:**
  - You must
    - Act in the best interests of service users.
    - Respect the confidentiality of service users.
    - Keep high standards of personal conduct.
    - Provide any important information about your conduct and competence.
    - Keep your professional knowledge and skills up to date.
    - Act within the limits of own knowledge, skills and experience and if necessary refer the matter to another practitioner.
    - Communicate properly and effectively with service users and other practitioners.
    - Keep accurate records.
    - Obtain informed consent to provide care or services (so far as possible).
<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th>Assessor’s / Self Assessor’s Signature</th>
</tr>
</thead>
</table>
| 6. Demonstrate familiarity with the legal and professional implications of intravitreal injection | **State & discuss:**  
- Individual legal responsibility.  
- Implications for the practitioner.  
- Accountability.  
- Duty of care/reasonable care.  
- Vicarious liability.  
- Informed /valid consent.  
- Mental capacity.  
- Local policies and procedures.  
- Negligence.  
- Registered practitioner understands that an ophthalmologist must be available on the phone and, if cannot manage immediate complications themselves, doctor must be in the department and available to assist with complications, whilst clinic is progress  
- The competency does not cover the injection to pregnant patients.  
- The competency does not cover intravitreal injections of Avastin (Bevacizumab) | |
<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th>Assessor’s / Self Assessor’s Signature</th>
</tr>
</thead>
</table>
| 9          | Is able to identify appropriate equipment and drugs and understands the process for delivering an intravitreal injection | **State & discuss:**  
- Describes the equipment used and demonstrates understanding of its use.  
- Rationale for the cleaning of the trolley prior to use.  
- Describes drugs used, how to use and how they work  
- Describes requirements for prescribers. |

| 10         | Discuss patient preparation prior to intravitreal injection insertion | **State & discuss:**  
- Informed / valid consent (as appropriate).  
- Limits of practice and patient selection.  
- Reassurance and explanation.  
- Previous injection history.  
- Correct area for injection selection  
- Any requirement to check IOP. |

| 11         | Demonstrate knowledge of the infection control issues relating to intravitreal injections. | **State & discuss:**  
- Main sources of bacteria for intravitreal injections associated infections.  
- Standard precautions for infection control.  
- Appropriate single use equipment.  
- Aseptic non-touch technique.  
- Hand hygiene and bare below the elbow.  
- Eye preparation.  
- Sharps safety including disposal care and maintenance.  
- Issues of iodine “allergy” and use of chlorhexidine. |
# Standard Operating Procedure (SOP)

**University Hospitals of Leicester NHS Trust**

**GH, LGH, LRI**

**Issue date:** 21/06/19

**Revision date:** 21/06/21

**Version:** 1

---

<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th>Assessor’s / Self Assessor’s Signature</th>
</tr>
</thead>
</table>
| **12**     | **Demonstrate knowledge of risk management issues relating to intravitreal injection and trust sharps and incident policies** | **State & discuss:**  
- Needle stick injuries:  
  - Incidence.  
  - Reasons for.  
  - Cost to the practitioner/organisation.  
  - Trust’s policy.  
- Best and safe practice to reduce risks  
- The Trust’s incident reporting procedure.  
- Awareness of clinical governance processes and audit, e.g. Safety Thermometer Data Collection Tool. |
| **13**     | **Demonstrate knowledge of the potential complications of intravitreal injection and how to reduce the risk** | **State & discuss:**  
- Signs and symptoms, management of the following:  
  - Wrong eye injected.  
  - Iodine administered in iodine allergic patient.  
  - Sub-conjunctival haemorrhage.  
  - Corneal abrasion.  
  - Cataract.  
  - Retinal tears/detachment.  
  - Air bubbles.  
  - Raised intraocular pressure.  
  - Vitreous wicks.  
  - Endophthalmitis.  
  - Post procedure infection. |

---

**Record of observation of intravitreal injections**

**Ward / Department .................................................................Name .................................................................**

---

**Title:** UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

**Authors:** Rossella Anzidei & Vasileios Konidaris

**Approved by MSS Board**  Date: 21/06/19  **Review date:** 21/06/21
<table>
<thead>
<tr>
<th>Date</th>
<th>Pt record Number</th>
<th>Comments</th>
<th>Signature of practitioner</th>
<th>Signature of Supervisor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board: Date: 21/06/19

Review date: 21/06/21
Record of supervised practice of preparation for intravitreal injections

<table>
<thead>
<tr>
<th>Date</th>
<th>Pt record Number</th>
<th>Comments</th>
<th>Signature of practitioner</th>
<th>Signature of Supervisor</th>
</tr>
</thead>
</table>

Ward / Department ........................................ Name ........................................

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
**Record of supervised practice of administering intravitreal injections**

<table>
<thead>
<tr>
<th>Date</th>
<th>Pt record Number</th>
<th>Comments</th>
<th>Signature of practitioner</th>
<th>Signature of Supervisor</th>
</tr>
</thead>
</table>

**Ward / Department** .........................................................**Name**  .........................................................

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

**Authors:** Rossella Anzidei & Vasileios Konidaris

**Approved by MSS Board**  **Date:** 21/06/19  **Review date:** 21/06/21
# Record of independent intravitreal injections

**Title:** UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

**Authors:** Rossella Anzidei & Vasileios Konidas

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21

---

<table>
<thead>
<tr>
<th>Date</th>
<th>Pt record Number</th>
<th>Comments</th>
<th>Signature of practitioner</th>
<th>Signature of Supervisor* record if supervised or observed</th>
</tr>
</thead>
</table>

---

* record if supervised or observed
<table>
<thead>
<tr>
<th>Ward / Department</th>
<th>Name</th>
</tr>
</thead>
</table>

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Intravitreal injecting - Competency Checklist – Skills

<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th>Assessor’s / Self Assessor’s Signature</th>
</tr>
</thead>
</table>
| 1 Has observed 20 injection pathways | Provide evidence  
- That 20 injections pathways have been observed.  
- That trainer happy for them to proceed | |
| 2 Has undertaken 20 injection preparations | Provide evidence  
- That 20 injections have been prepared.  
- That trainer happy for them to proceed | |
| 3 Has undertaken 30/50 observed or supervised injections | Provide evidence  
- That 30-50 injections have been performed under supervision.  
- That trainer happy for them to proceed.  
- They have observed a number of different practitioners to observe differing techniques.  
- Kept a record of all patients and audited patients for outcome. | |
| 4 Prepares room and equipment | Under observation:  
- Checks room and equipment is clean and suitable  
- Ensures all equipment present and suitable  
- Ensures all drugs are present and not expired | |
| 5 Checks notes | Under observation:  
- Checks notes and ensures completed consent, clinical notes with up to date examination, no contraindications or concerns, drug prescribed  
- Ensures correct drug | |

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th>Assessor’s / Self Assessor’s Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td><strong>Patient discussion and comfort</strong></td>
<td><strong>Under observation:</strong>&lt;br&gt;  - Identifies patient, checks allergies, checks medical history changes&lt;br&gt;  - Checks patient understands procedure&lt;br&gt;  - Checks patient understands HCP&lt;br&gt;  - Positions patient&lt;br&gt;  - Ensure patient comfort and advice how to say if not comfortable&lt;br&gt;  - Completes miniWHo checklist and marks eye</td>
</tr>
<tr>
<td>7</td>
<td><strong>Is able to identify appropriate equipment and understands the process for delivering an intravitreal injection</strong></td>
<td><strong>Under observation:</strong>&lt;br&gt;  - Assembles equipment as identified in procedure and in accordance with manufacturer’s instructions.&lt;br&gt;  - Cleans trolley if not done&lt;br&gt;  - Sterile gloves, packs, syringes and needles, drops opened onto sterile field.&lt;br&gt;  - Sterile gallipot/tray filled with 5ml normal saline 0.9% and approximately 5mls Iodine solution.&lt;br&gt;  - Instils anaesthetic and iodine drops</td>
</tr>
<tr>
<td>8</td>
<td><strong>Demonstrate procedure for intravitreal injection.</strong></td>
<td><strong>Under observation:</strong>&lt;br&gt;  - Perform hand hygiene and on sterile gloves&lt;br&gt;  - Draws up and prepares drug as required&lt;br&gt;  - Reconfirms eye&lt;br&gt;  - Clean skin with iodine&lt;br&gt;  - Instil anaesthetic/iodine drops</td>
</tr>
<tr>
<td>8</td>
<td><strong>Continued</strong></td>
<td><strong>Procedure continued:</strong>&lt;br&gt;  - Inserts speculum&lt;br&gt;  - Marks site&lt;br&gt;  - Administer the injection&lt;br&gt;  - Remove speculum&lt;br&gt;  - Dispose of needle in appropriate sharp bin</td>
</tr>
</tbody>
</table>

**Title:** UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

**Authors:** Rossella Anzidei & Vasileios Konidaris

**Approved by MSS Board**<br>**Date:** 21/06/19<br>**Review date:** 21/06/21
<table>
<thead>
<tr>
<th>Competency</th>
<th>Competency Checklist</th>
<th>Assessor’s / Self Assessor’s Signature</th>
</tr>
</thead>
</table>
| 9 Is able to identify successful/unsuccessful intravitreal injection. | **Under observation can demonstrate:**  
- Signs of successful injection.  
  - Minimum discomfort to the patient (during and after procedure).  
  - No pain.  
  - No significant sub-conj bleeding  
  - Clear injection site/no vitreous wick.  
  - Patient can detect hand movement vision  
  - Seeks urgent medical care if issues. | |
| 10 Safe discharge | **Under observation can:**  
- Provide and advise on any postop prescription  
- Check next appointment date  
- Advice on symptoms of concern and contact if problems | |
| 11 Documentation | **Under observation can:**  
- Complete documentation correctly side, drug, prescription of post-op drops, name and any GP letter | |
Competency sign off form: Non Medical Intravitreal Injecting

This form must be completed and returned to your line manager once you have gathered all your evidence to support your claim of competence and been assessed in practice.

Name: 

Designation: 

Ward / Department: 

Date of study day: 

Date of original sign off as independent injector: 

Date of last Assessment: 

I feel competent in this procedure and understand the competency statement, action and outcome. Having received appropriate training, I accept responsibility for my own competence and have discussed this role as part of my job description with the person to whom I am managerially accountable.

Your signature: ………………………………………………………………………………………………………

I have assessed ……………………………………… in this competency and feel that both practice and knowledge meet the required standard.

Assessor’s signature: ………………………………………………………………………………………………………

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
## Appendix 3. Reflective practice template

<table>
<thead>
<tr>
<th>O/S/I*</th>
<th>Date</th>
<th>Brief description of episode and comments or reflections by practitioner</th>
<th>Trainer/assessor comments and constructive feedback</th>
<th>HCP sign</th>
<th>Trainer print and sign</th>
</tr>
</thead>
</table>

*O/S/I = Observed/supervised/independent

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
| Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs) |
| Authors: Rossella Anzidei & Vasileios Konidaris |
| Approved by MSS Board | Date: 21/06/19 | Review date: 21/06/21 |
# Appendix 4 SOP

## Standard Operating Procedure

**Title** Administration of Intravitreal Injections of anti-VEGF medication for macular disease by non-medical injectors

**Department:** Ophthalmology

**SOP Summary**

*This SOP describes the equipment and procedure required for the administration of medication via Intravitreal injection.*

**Version:** 1.0

**Approved:**

<table>
<thead>
<tr>
<th>Clinical Unit or Department:</th>
<th>Leicester Royal Infirmary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of author(s)</td>
<td>Ms Rossella Anzidei (Consultant Ophthalmologist)</td>
</tr>
<tr>
<td></td>
<td>Mr Vasileios Konidaris (Consultant Ophthalmologist)</td>
</tr>
<tr>
<td>Name of responsible individual</td>
<td></td>
</tr>
<tr>
<td>Approved by:</td>
<td></td>
</tr>
<tr>
<td>Ratified by:</td>
<td></td>
</tr>
<tr>
<td>Date issued:</td>
<td></td>
</tr>
<tr>
<td>Review date:</td>
<td></td>
</tr>
<tr>
<td>CQC relevant domains</td>
<td>Non-health care Practitioners, Nursing, orthoptists, optometrists, ophthalmologists,</td>
</tr>
<tr>
<td>Target audience:</td>
<td></td>
</tr>
</tbody>
</table>

---

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board: Date: 21/06/19  Review date: 21/06/21
1. Introduction
This standard operating procedure (SOP) is for all non-medical injector health care professionals (HCPs) whether nursing, orthoptist or optometrist, who have been allocated to carry out intravitreal injections for patients with macular disease.

2. Scope
The purpose of this SOP is to describe the preparation and process for carrying out intravitreal injections in the ophthalmology service.

3. Process
3.1 Consent, prescribing and documentation
The plan for treatment is discussed with the patient in the consultant led clinics; this includes treatment modality, course of treatment, consent for treatment, any commissioner therapy application and provision of the intravitreal injection patient information leaflet.

Before starting the procedure the HCP must ensure that the patient has been given the relevant information and written consent for the procedure has been obtained prior to the first injection taking place. The HCP should also check the consent for the course of treatment is up to date. This process will ensure that the patient is aware of the rationale for the procedure and of all potential complications.

The HCP must ensure that the drug has been prescribed by a doctor or independent prescriber and that this is documented correctly.

4.2 Exemptions to treatment by the HCP
The intravitreal injection procedure should not be performed by the HCP if:

- The patient will not provide valid consent or refuses treatment by the HCP
- The HCP does not feel it is safe to proceed or has concerns performing the injection
- The HCP does not have immediate access to medical support (ie the doctor should either be present on site or, if the HCP is competent to manage immediate emergencies, ophthalmology managers

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
by phone with a pathway in place to see a doctor urgently with the appropriate safe timescale if required, once the HCP has undertaken first treatment).

- The consultant or senior fellow decides that the patient requires a member of the medical team to perform the procedure
- A patient has had repeated previous complications such as central retinal artery occlusion and required paracentesis.
- Active eyelid and/or ocular surface disease such as blepharitis
- Other high risk ocular comorbidity e.g. retinal detachment
- Other medical conditions making the administration difficult e.g Parkinson’s disease, difficult positioning or ocular fixation problem such as nystagmus

4.3 Prior to intravitreal injection commencing
The HCP will:

- Review the patient’s notes and:
  o Ensure the patient has been referred for treatment by the consultant or trained assessor in charge of the clinic.
  o Ensure that the drug has been prescribed correctly.
  o Confirm that a recent retinal and macular examination has been taken place and details of the examination are recorded in the notes. If not, a review must be obtained before intravitreal injection taking place.
  o Confirm that the patient has undergone all the relevant checks and tests in accordance with clinic protocols
  o Check if the patient has any allergies and if the patient has a definite allergy to povidone iodine ensure that this has been be verified by the consultant so an alternative preparation can be used. When patients are allergic to povidone iodine, chlorohexidine gluconate can be used.
  o Check a recent visual acuity test has been performed
  o Ensure the patient shows no signs of infection such as conjunctivitis and blepharitis, if there possible signs of infection this must be discussed with the doctor and a clear treatment plan put in place.
  o Check the patient’s medical history as HCPs must not inject the patient if the patient is suffering from:-
    - Unstable angina
    - Uncontrolled hypertension
    - Any evidence of infection
    - Ocular infection

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Recent MI or CVA
Pregnancy
Previous allergy to the drugs
Too high INR

- Check that the consultant or fellow in charge of the injection session is available in the injection service. The injection list must not commence until the senior doctor in charge of the session is available. If the HCP is trained to instigate initial management of complications, check there is a senior doctor available on the phone and someone who can receive any urgent complications.
- Review the injection room facilities, ensuring it is clean and safe for use.
- Check all equipment is ready for the session.
- Ensure all drugs are present and in date
- Ensure that a designated nurse or healthcare assistant/technician is present in the treatment room to assist with the procedure.
- Ensure that the assistant has followed the correct hygiene precautions and aseptic technique in preparing the patient for the injection.

4.4 Preparation of the patient

- The HCP should introduce themselves to the patient and confirm the patient’s identity in accordance with the trust policy, ensuring that the patient states their name and date of birth.
- The HCP should explain to the patient that they will be administering the intravitreal injection prescribed by the doctor or independent prescriber.
- The HCP should again verbally confirm with the patient their allergy status and past medical history including checking for hypertension and whether they have suffered a recent heart attack or stroke or attended hospital since their last injection. This will prevent any untoward side effects from medications used during this procedure.
- The patient consent form should be checked and the HCP should confirm with the patient which eye(s) is to be treated. The patient’s eye(s) to be treated must be marked according to trust policy, if there is a discrepancy between the notes and patient the consultant or fellow in charge of the clinic should be consulted.
• The abbreviated surgical safety checklist should be completed and both the injecting practitioner and assistant must check and verbally confirm.
• The Correct Identity of the patient.
• The Correct Eye to be injected and eye is marked.
• The drug to be injected.
• The HCP should check if the eye to be treated is phakic or pseudophakic. Document this in the patient’s clinical record as this will influence the choice of injection site.
• If the patient has a history of glaucoma and/or previous complications from an injection procedure this should be noted.
• The procedure should be fully explained, allowing time for the patient to ask questions.

4.5 Equipment required to perform Intravitreal Injection
• Proxymetacaine or Oxybuprocaine hydrochloride eye drops
• Iodine skin scrub (10% aqueous solution) or Tisept solution (Chlorhexidine gluconate 0.015%) if patient has skin sensitivity or allergy to Povidone Iodine.
• Povidone Iodine 5% eye drops, if the patient is allergic to Iodine the use of Chlorhexidine 0.02% must be confirmed with the doctor.
• Tissues
• Injection pack
• Injection drug
• Dressing trolley cleaned thoroughly with detergent, followed by 70% isopropyl alcohol.
• Surgical face mask
• Sterile gloves
• Hand antiseptic (4% Chlorhexidine Gluconate or 7.5% Iodine)
• Sharps container
• Clinical Waste bin

All eye drops and equipment must be checked before use in accordance with trust policy. All eye drops must be instilled in accordance with the policy and procedure guidelines and the relevant patient group directions (PGDs).

4.6 Procedure
• Ensure that the patient is positioned comfortably on the couch or wheelchair.
• Ensure that the patient knows how to communicate if they are suffering any discomfort during the procedure e.g. asking HCP to pause procedure.

• Open pack:
  o The assisting practitioner must decontaminate hands prior to opening out the pack
  o A strict aseptic technique must be used to prevent potential contamination of the sterile field and the equipment.
  o The injection pack should only be opened when patient is on the couch and ready to receive treatment.

• Instil two drops of either proxymetacaine hydrochloride 0.5% or oxybuprocaine hydrochloride 0.4% eye drops as per PGD.

• Wear a face mask.

• Staff must be dressed bare below the elbows to carry out this procedure

• Check that the correct medication is selected for the patient, the expiry date, and the dose to be injected before injecting the prescribed medication.

• Decontaminate hands following hand hygiene policy and using chosen antiseptic (4% Chlorhexidine gluconate or 7.5% Povidine iodine) perform aseptic hand wash

• Dry hands thoroughly and apply sterile gloves

• Instil one drop of prescribed 5% Povidone Iodine eye drops into the eye for injection at least 3 minutes prior to injection. If the patient is allergic to Iodine, instil one drop of Chlorhexidine 0.02% eye drops but ensure this is a true allergy and is discussed with the doctor in clinic as iodine is much more effective.

• Clean the eyelids with 10% iodine aqueous solution skin scrub as outlined in PGD, if patient allergic to iodine use Tisept solution (Chlorhexidine gluconate 0.015% and Cetrimide 0.1%).

• Apply lid speculum

• Instil additional drop of 0.4% oxybuprocaine

• Mark the injection site by measuring 4.0mm from limbus for phakic eyes and 3.5mm from the limbus in pseudophakic eyes.

• Administer drug by injection at marked site should this be superotemporal

• Establish that patient can see hand movements (to ensure no significant change in vision).

• Apply Chloramphenicol eye drops

• Remove eyelid speculum and wash off iodine from skin with sterile saline solution

• Remove used pack and ensure that the needle and any other sharps are disposed of directly in to the sharps container.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
- Used sterile gloves, surgical mask to be discarded in clinical waste bag together with all other clinical waste.
- Hand decontamination to be undertaken prior to continued patient care and documentation of procedure
- Dressing trolley to be wiped down with 70% alcohol wipes between patients
- Give patient written after care advice and a contact telephone number in case they have any cause for concern. Concerns would include severe pain, a significant drop in visual acuity. Inform patient where they can call or return to if they experience any problems.
- Ensure patient has a follow up appointment.
- Give discharge medications as per PGD

4.7 Documentation
- GP letter to be completed on records, filing a copy in the notes
- Record treatment clearly in the patient’s health records – including the drug injected, the eye injected date, time, name and signature.
- If an unexpected event occurs, document and complete and report the incident. This is necessary to facilitate communication within the team, meet legal requirements of practice and enable monitoring over a time period.

4.8 Drugs Used for Procedure
4.8.1 Proxymetacaine hydrochloride 0.5% eye drops minims.
Legal status: Prescription only medicine.
Dose: Once only
Method and route of administration:
Follow standard eye drop instillation procedure. Instil two drops to the outer aspect of the lower fornix of the affected eye.
Advice to patients
- Drop may sting
- Patients should refrain from touching or rubbing their eyes due to loss of corneal sensation
- Advise the hospital of any unwanted effects.

Adverse drug reactions
- Burning and stinging
- Transient blurring of vision on instillation

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
• Acute, intense and diffused corneal epithelial keratitis
• Iritis with descemetitis
• Local anaesthetic eye drops cause a temporary (approximately half an hour from administration) elimination of the blink reflex

**Record keeping**
The administration of proxymetacaine hydrochloride 0.5% eye drops will be recorded in the patient’s case notes, recording date, time and signature of HCP.

**Information to be documented:**
• Name, form and strength of medicine to be documented in full
• Date, which eye time and dosage administered

4.8.2 Oxybuprocaine hydrochloride 0.4% eye drops (benoxinate) minims.
**Legal status:** Prescription only medicine.
**Dose:** Once only
**Method and route of administration:**
Follow standard eye drop instillation procedure. Instil two drops to the outer aspect of the lower fornix of the affected eye.

**Advice to patients**
• Drop may sting
• Patients should refrain from touching or rubbing their eyes due to loss of corneal sensation
• Advise the hospital of any unwanted effects.

**Adverse drug reactions**
• Transient stinging, local irritation
• Superficial punctuate keratitis or oedema
• Ineffective tearing due to temporary elimination of the blink reflex
• Hyperaemia
• Oedema

**Record keeping**
The administration of oxybuprocaine hydrochloride 0.4% eye drops will be recorded in the patient’s case notes, recording date, time and signature of HCP.

**Information to be documented:**
- Name, form and strength of medicine to be documented in full
- Date, which eye time and dosage administered
- Signature of HCP

### 4.8.3 Povidone Iodine 5% Eye Drops

**Legal status:** Prescription only medicine.

**Dose:** One drop into the lower conjunctival sac and onto lid margins 3 minutes prior to administration of intravitreal injection.

**Method and route of administration:**
One drop into the lower conjunctival sac.

**Advice to patient**
Drop may sting

**Route of administration**
Topically to the lower conjunctival sac and lid margins

**Frequency of administration and maximum dosage**
Instil one drop in to lower conjunctival sac and onto lid margins prior to administration of intravitreal injection.

**Record keeping**
The administration of Povidone iodine 5% eye drops will be recorded in the patient’s case notes, recording date and time of administration and signature and designation of HCP following prescription by a doctor.

### 4.8.4 Anti-VEGF medication

This may be Lucentis (Ranibizumab) or Eylea (Aflibercept).

### 4.8.5 Lucentis (Ranibizumab)

**Legal status:** Prescription only medicine.

**Dose:** Supplied as an injection 10mg/ml, dose is once only 500mcg once a month for three months with further injections as needed

**Method and route of administration:**
By intravitreal injection, for supply of treatment:

**Advice to patient**
- Advise if any loss of vision immediately
- Advise the hospital of any unwanted effects.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)
Adverse drug reactions
- Nausea
- Headache
- Eye pain
- Conjunctival and retinal haemorrhage
- Oedema
- Vitreous detachment
- Retinal Detachment
- Endophthalmitis

Record keeping
The administration of Anti-VEGF medication must be recorded in the patient’s records including date and time of administration and signature and designation of HCP.

4.8.6 Eylea (Aflibercept)
Legal status: Prescription only medicine.
Dose: Supplied as an injection 40mg/ml, dose is 2mg aflibercept (50 microlitres-0.05ml)) once a month for three months followed by one injection every two months. After 12 months of treatment the treatment interval may be extended depending on the patient’s condition
Method and route of administration:
By intravitreal injection, for supply of treatment
Advice to patient
- Advise if any loss of vision immediately
- Advise the hospital of any unwanted effects.
Adverse drug reactions
- Nausea
- Headache
- Eye pain
- Conjunctival and retinal haemorrhage
- Oedema
- Vitreous detachment
- Blindness
- Hypopyon
- Endophthalmitis,

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
**Title:** UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

**Authors:** Rossella Anzidei & Vasileios Konidaris

**Approved by MSS Board**

**Date:** 21/06/19

**Review date:** 21/06/21

- Uveitis,
- Retinal detachment
- Raised intraocular pressure
- Conjunctival and retinal haemorrhage

**Record keeping**

The administration of Eylea medication 0.05ml will be recorded in the patient’s case notes, including date, time of administration and signature and designation of HCP.

**4.8.7 Chloramphenicol 0.5% Eye Drops**

**Legal status** prescription only medicine

**Route of administration**
Topically to the lower conjunctival sac

**Frequency of administration and maximum dosage**
To instill one drop in the conjunctival sac after the intravitreal injection

**Side effects**
Transient irritation, burning, stinging and sensitivity reactions such as itching and dermatitis

**Contraindications**
Hypersensitivity to the active substance chloramphenicol or to any of the excipients, myelosuppression during previous exposure to chloramphenicol, known personal or family history of blood dyscrasias including aplastic anaemia.

**4.8.8 Hypromellose 0.3% Eye Drops**

Supplied to the patient to take home

**Legal status:** CE marked medical device

**Route of administration**
Topically to the lower conjunctival sac unless Doctor requests otherwise

**Frequency of administration and maximum dosage**
One drop as needed

**Side Effects**
Eye irritation

**Contraindications**
Children <3 years old
Breastfeeding
Contact lenses

4.9 Potential risks of Intravitreal injection
The risks of intravitreal injections include:
- Pain
- Bleeding (subconjunctival, vitreous haemorrhage)
- Retinal tear / detachment
- Cataract (from inadvertently hitting the lens)
- Infection (endophthalmitis)
- Loss of vision (from any of above)
- Loss of the eye (from a severe infection)
- Raised intraocular eye pressure

Also risk of needlestick injury to staff.

4.9 Managing complications immediately

Intravitreal injections carry risks and one potential risk is if the intraocular pressure (IOP) rises to a very high level which then occludes the central retinal artery. This could result in permanent irreversible vision loss if the IOP is not reduced within a short period of time. It is not always possibly for a doctor has been present in the eye department to provide assistance and to continue to deliver a safe level of capacity of care to avoid unsafe delays to injections. Delays to injection care could result in increased vision loss from macular conditions. The risk of central retinal artery occlusion (CRAO) is very rare, less than 1 in 1000 injections.

After an intravitreal injection, each patient is asked to count fingers or detect whether a hand is moving in front of the patient, to ascertain whether the patients’ central retinal artery is adequately perfused. If the IOP has elevated to a critical level, then the CRA could be occluded by this raised IOP and the patient could lose vision permanently without intervention. The recommended intervention is to administer 500mg acetazolamide tablets orally and one drop of apraclonidine 1% STAT in the affected eye. The incident should be fully documented in the electronic patient record system and in the patients’ notes.
Post injection vision check: if unable to CF or see HM then senior assessor will need to examine the patient and determine why the vision has been lost. Variety of reasons exists such as vitreous haemorrhage, lens trauma or raised IOP occluding CRA. In case of the latter the following steps should be followed:

1) administer one drop of apraclonidine 1% STAT to the affected eye
2) administer 500mg po acetazolamide STAT
3) doctor called

Any complications or untoward incidents must be reported immediately to the supervising consultant or senior fellow and then via the trusts incident reporting system. All cases of endophthalmitis must be reported as an incident and involve the local infection control team.

5. Approval
This SOP is part of the HCP policy and was approved by the insert committee name committee and ratified by the committee name.

6. Dissemination and Implementation
This SOP will be disseminated following ratification, to all staff involved in the administration of intravitreal injections, and will be communicated to key stakeholders via email and highlighted at insert name of meetings or other methods. This SOP will be published on the intranet site.

7. Review and Revision Arrangements
This document will initially be reviewed on an annual basis by the SOP Owner/Authors, for two years (if practice new) and then every three years after. Changes to the legislation of the administration of intravitreal injections by non-medical personal will trigger a review of this SOP.

8. Document Control and Archiving
The current and approved version of this document can be found on the Trust’s intranet site. Should this not be the case, please contact the SOP owner / author.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cataract</td>
<td>Opacity of the lens</td>
</tr>
<tr>
<td>Endophthalmitis</td>
<td>An inflammatory condition of the intraocular cavities</td>
</tr>
<tr>
<td>Intravitreal Injection</td>
<td>The route of administration of a drug inside the eye</td>
</tr>
<tr>
<td>Retinal detachment</td>
<td>Separation of the neurosensory retina from the pigment epithelium</td>
</tr>
<tr>
<td>Hypopyon</td>
<td>Pus in the anterior chamber</td>
</tr>
<tr>
<td>Oedema</td>
<td>Swelling</td>
</tr>
<tr>
<td>Intraocular eye pressure</td>
<td>The fluid pressure inside the eye</td>
</tr>
<tr>
<td>Anti-VEGF medication</td>
<td>Anti-vascular endothelial growth factor</td>
</tr>
</tbody>
</table>

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board  Date: 21/06/19  Review date: 21/06/21
## Appendix 7 Risk Assessment

<table>
<thead>
<tr>
<th>Department / Directorate</th>
<th>Ophthalmology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>This risk assessment is to assess any risks associated with non-medical practitioners expanding their role and undertaking Intravitreal injections for patients in the medical retina service.</strong></td>
<td></td>
</tr>
</tbody>
</table>

Intravitreal injections are associated possible complications such as:

- Infection (endophthalmitis)
- Retinal Detachment
- Cataract
- Raised intraocular pressure

The above complications could occur for all competent practitioners whether medical or non-medical professional. These complications are rare. However some are sight threatening, especially if the complication is not spotted or some immediate treatment is not performed.

Risks associated with a non-medical HCP carrying out this procedure include:

- Perception by patient/family that complication was due to injection not performed by doctor
- Failure of HCP to detect complication
- Having the experience and ability to manage complications which may occur;
- Non enough staff or time to undergo training
- Not enough senior staff or consultant time to supervise and sign off training
- Capacity issues creating pressure to have excessive numbers on injection clinics

<table>
<thead>
<tr>
<th>Existing controls in place when risk was identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The guidelines from the Royal College of Ophthalmologists are followed.</td>
</tr>
<tr>
<td>• Compliance with Consent Policy</td>
</tr>
<tr>
<td>• Aseptic technique used.</td>
</tr>
<tr>
<td>• The procedure would be done in a clean environment compliant with national guidance.</td>
</tr>
<tr>
<td>• Medical consultant leadership and supervision of service.</td>
</tr>
<tr>
<td>• An Incident Reporting process in place for adverse events.</td>
</tr>
<tr>
<td>• Records are kept of procedures carried out and complications noted.</td>
</tr>
<tr>
<td>• An audit of the service is regularly carried out.</td>
</tr>
<tr>
<td>• Regular patient feedback is sought.</td>
</tr>
<tr>
<td>• Process in place for reporting cases of endophthalmitis.</td>
</tr>
</tbody>
</table>

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Appendix 8: PATIENT SATISFACTION QUESTIONNAIRE

1. The Practitioner introduced herself and was friendly and approachable

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Uncertain</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disagree</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. When I attended for injection the practitioner carefully checked everything before treating me

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Uncertain</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disagree</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. I was happy with my time taken for my visit today

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Uncertain</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disagree</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. The procedure for having my injection was explained clearly to me

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Uncertain</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disagree</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. The Practitioner answered all my questions and discussed any concerns I had

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21

Governance structures in place where issues / concerns can be raised.
A complaints system is in place where these are reviewed and lessons are learned and shared.
Regular follow up of patients are performed post treatment in the eye clinic.
Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners(s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidarlis

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21

6. The practitioner seemed knowledgeable and competent

7. The Practitioner made sure I was comfortable during my injection

8. If I have further injections I would be happy for the practitioner to do this

9. Overall how would you rate your care and treatment during your appointment today?

10. Any further comments
As part of the new role for non-medical Practitioners lays the ability to assess patients in the medical retina clinics, before delivering them intravitreal injections.

**Aim:** To be able to safely and competently assess a patient's OCT making a clinical decision on the patient's treatment pathway, ensuring protocol is adhered to at all times.

**Key Staff:** Non-medical Practitioners

**Reports to:** Consultant Ophthalmologist

**Key Criteria:**

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
To have a good knowledge and understanding of the anatomy and physiology of the eye, in particular the retina
To have a good knowledge and understanding of various eye conditions, in particular retinal vein occlusions, Diabetes and AMD.
To be able to assess the patients OCT scan and ensure the correct treatment outcome is chosen and within the appropriate timescale for each individual case
To be able to work autonomously
To be able to accurately record findings in the patient's notes
To be able to complete any other paperwork required and dictate letters so patients are informed of the outcome.

Evidence Portfolio
Alongside completing this competency booklet a portfolio of each individuals work should also be completed, with a minimum of fifty completed records enclosed, whilst ensuring patient confidentiality is adhered to, and to be shown to the assessor if required to do so.

Diabetic retinopathy
Diabetic retinopathy is the leading cause of legal blindness in the working age population in industrialised countries. This loss of vision occurs as a result of several mechanisms, the most common cause to date being attributed to diabetic macular oedema (DMO).

Management of patients with DMO has evolved over the last few decades from the use of laser as the old gold standard to much newer therapies. Recent innovative research focusing on the use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat DMO has shown particular promise due to overall efficacy. Ranibizumab, the first anti-VEGF agent to gain approval for the treatment of DMO in 2013, was based on multiple studies including the RISE and RIDE studies. Aflibercept later obtained licence for treating DMO in 2014 based on the VIVID-DME and VISTA-DME studies. Despite similarities of the two anti-VEGF agents, the pharmacodynamics of aflibercept and ranibizumab differ greatly.

Retinal vascular occlusion
Central Retinal Vein Occlusion (CRVO) is the second most common retinal vascular disease after diabetic retinopathy and is known to affect one person per 1000 at any one time. CRVO is classified into two types: ischemic and non-ischemic. Ischemic CRVO, clinically more severe...
severe of the two, accounts for 20% of acute presentations and results in a significant increase in vascular endothelial growth factor A. Non-ischemic CRVO is known to convert to ischemic CRVO in approximately a third of the cases. CRVO commonly affects one eye; however in approximately 10% of the cases it may be bilateral. There is also an associated 1% risk per year of known CRVO patients to develop RVO in the second eye.

Macular oedema, a well-known complication of CRVO, is characterized by hypoxic retinal tissue release of vascular endothelial growth factor (VEGF) and inflammatory mediators such as interleukin (IL)-8, angiopoietin (ANG)-2 and intercellular adhesion molecule (ICAM)-1. Both these VEGF dependent and inflammatory pathways result in fluid accumulation within the retina and reduced visual acuity. Self-resolution of the intraretinal fluid is noticed in approximately a third of cases with non-ischemic CRVO and associated macular oedema. A plethora of therapeutic modalities have been introduced within the last years regarding the treatment of macular oedema related to CRVO when self-absorption of the intraretinal fluid does not occur. Treatment options include laser photocoagulation, intravitreal steroid use, and newer therapies with anti-VEGF.

Multiple anti-VEGF therapies have been used in the treatment of CRVO related macular oedema including bevacizumab, ranibizumab, and aflibercept. The efficacy of these anti-VEGF agents was demonstrated by numerous studies, notably the CRUISE study for ranibizumab, and the extension studies HORIZON and RETAINS, COPERNICUS and GALILEO study for aflibercept, and numerous studies with level 2 and 3 evidences for bevacizumab. Most of them investigated the anatomical and functional response to treatment with anti-VEGF through changes in central retinal thickness (CRT) and visual acuity.

Branch retinal vein occlusion (BRVO) is a relatively common vascular retinal condition with an incidence of 0.5% to 1.2%. Macular oedema secondary to a BRVO typically causes significant visual loss with little propensity to improve without treatment. This loss of vision occurs as a result of several mechanisms, the most common cause being attributed to macular oedema.

Much like DMO, management of patients with MO secondary to BRVO has evolved over the last few decades from the use of laser, to anti-VEGF therapy. For BRVO with MO, there are robust clinical trial data for the clinical effectiveness of ranibizumab and aflibercept. Ranibizumab was the first anti-VEGF agent to gain approval in the United Kingdom for the treatment of MO secondary to BRVO in 2013. Its approval was based on the BRAVO study, which showed that the mean gain in BCVA at 6 months was 18.3 letters with 0.5mg ranibizumab compared to 7.3 letters with the sham injection. Aflibercept obtained licence for treating MO secondary to BRVO in 2016 based on the VIBRANT study.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners(s) Standard Operating Procedure (LocSSIPs)
Optical Coherence Tomography

Optical coherence tomography (OCT) technology allows the acquisition of cross-sectional images of the retina with semi-histologic resolution. It permits to define the location and nature of the changes in the retina and adjacent structures and objectively evaluates the thickness of the retina and surrounding structures. These capabilities allow detection of newly emerging fluid and/or intraretinal or subretinal tissue and tissue below the retinal pigment epithelium (RPE) and assess the response to anti-vascular endothelial growth factor (VEGF) drugs.

The images are presented in a colour (or gray) scale based on the different reflectivity of the tissue structures. More concisely, tissues that reflect more light or disperse more light are shown in red and white, respectively, while the ones that reflect or disperse less light are shown in blue and black. Tissues that moderately reflect light are shown as green or yellow. It should be noted that the colour shown in the images represents the optical properties of the tissues and not the tissues themselves. Therefore, the image is not real but represents the true dimensions of the measured structures.

Normal eye

The vitreous transmits light without reflecting it and is depicted in black in OCT images (Figure 1). The posterior hyaloid usually is indistinguishable from the retinal surface except when the posterior vitreous is detached and appears as a weakly reflective band. The choriocapillaris and choroid are highly reflective layers, because they are vascular and limit light penetration into the deeper layers. Blood vessels are identified by their high reflectivity and the masking effect generated on adjacent tissues (Table 1).
Figure 1. OCT of a normal eye.

Table 1. Reflectivity Patterns of the Retinal Structures in Normal Eyes

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperreflectivity pattern</td>
<td>Nerve fiber layer, thicker in the nasal portion (red), RPE and choriocapillaris (red)</td>
</tr>
<tr>
<td>Normal reflectivity pattern</td>
<td>Inner and outer plexiform layer (yellow-green), inner and outer nuclear layers (blue)</td>
</tr>
<tr>
<td>Hyporeflectivity pattern</td>
<td>Photoreceptor layer</td>
</tr>
</tbody>
</table>

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSIPs)

Authors: Rossella Anzidei & Vasileios Konidarlis
Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Intraretinal and Subretinal Fluid

Intraretinal fluid can occur either diffusely; creating increased retinal thickness and reduced retinal reflectivity, or appear localized in non-reflective well-defined cysts (cystic macular oedema). Subretinal fluid corresponds to the accumulation of a clear or lipid-rich exudate (serous fluid) in the subretinal space, i.e., between the neurosensory retina and the underlying RPE (Figure 2).

![Figure 2. Intraretinal and subretinal fluid](image)

Spectral-Domain OCT

The spectral-domain (SD) OCT devices include a spectrometer in the receiver that analyzes the spectrum of reflected light on the retina and transforms it into information about the depth of the structures according to the Fourier principle. This technology eliminates the need to
mechanically move the reference arm with the consequent increase in the speed with which images are received and axial resolution in time-domain (TD) OCT.

Vascular endothelial growth factor (VEGF)

VEGF-A is an important permeability inducer and is about 50,000 times more potent than histamine. It is also a potent mitogen in endothelial cells and may have an important role in maturing of new blood vessels through pericytes. VEGF-A is involved in physiological angiogenesis in adults, for example, in the female reproduction cycle. In addition, VEGF-A mRNA is expressed in various healthy human adult tissues that do not show angiogenesis, such as the epithelium of the choroid plexus in the brain, the glomerular epithelium in the kidney, the gastrointestinal mucosa and hair follicles. It has been suggested that VEGF-A maintains the integrity of endothelial cells via anti-apoptotic signalling. VEGF-A has been recognised as an important neuroprotectant in the central nervous system.

Although mechanistic studies have suggested that VEGF-induced volumetric blood flow to the retina may be partially responsible for neuroprotection, ex vivo retinal cultures have revealed a direct neuroprotective effect for VEGF-A. VEGF receptor-2 expression has been detected in several neuronal cell layers of the retina, and functional analyses have shown that VEGF-2 is involved in retinal neuroprotection. It has been shown that VEGF-A is secreted by RPE cells, on their basal side, i.e. the side adjacent to the choriocapillaris, and the 3 VEGFRs are expressed in choriocapillaris endothelial cells, on the side facing retinal pigment epithelial cells. It has long been known that loss of RPE cells in the human eye causes atrophy of the choriocapillaris. Since VEGF is highly regulated by hypoxia, a feedback mechanism must exist in these epithelia to promote physiological formation of new blood vessels when tissue oxygenation is low.

VEGF and pathology

The predominant role of VEGF-A in the development of pathological angiogenesis, such as that occurring in tumours and ischemic and inflammatory processes was widely demonstrated in the last decade. In hypoxic states, VEGF is secreted by RPE cells. This factor induces endothelial cell proliferation and increases vascular permeability. It has been shown in several models that VEGF-A is required and sufficient for development of new blood vessels in the retina and the iris. As already mentioned, VEGF-A has been identified as a primordial factor in the neovascular response induced by retinal ischemia. Therefore, VEGF-A levels are increased in the vitreous and retina of patients with neovascularisation secondary to proliferative diabetic retinopathy, venous occlusion or retinopathy of
prematurity. Vascular endothelial growth factor A (VEGF-A) regulates angiogenesis and vascular permeability in the eye, both in physiological and pathological processes.

It is possible to inhibit every step of the angiogenesis cascade induced by VEGF: VEGF synthesis may be inhibited by inhibiting the synthesis of the corresponding mRNA or by inhibiting transcription. The effect of VEGF may also be directly inhibited, by inhibiting protein action. This is the mechanism used in anti-VEGF therapies. Treatment of AMD, DMO and MO secondary to RVOs with anti-VEGFs is thus considered to be a turning point since its emergence has allowed a more direct approach to its selective inhibition.

Three drugs in this class are currently used: ranibizumab (Lucentis®), aflibercept (Eylea®) and bevacizumab (Avastin®), of which only the first two have been approved for this therapeutic indication.

**Ranibizumab (Lucentis®)**

Ranibizumab is a Fab fragment of a recombinant humanized monoclonal antibody with high affinity for VEGF-A. Ranibizumab has a solid clinical development program for this therapeutic indication, involving over 7,000 patients. Ranibizumab binds to an amino acid chain common to all VEGF-A isoforms, thus rendering them inactive, reducing retinal and choroidal angiogenesis and halting the increase in capillary permeability.

It has been shown in animal models that ranibizumab effectively penetrates the retina and the subretinal space after intravitreal injection. Its systemic half-life is short (2-3 hours, following intravitreal administration) and systemic clearance is fast, which makes its administration safe. The average vitreous elimination half-life is approximately 10 days. The recommended dose is 0.5 mg.

Treatment includes a loading phase, consisting of 3 monthly injections, in the first 3 months, and a maintenance phase, where retreatment is decided according to disease progression, mostly evaluated in monthly visits through VA and OCT criteria, at least during the initial stage or recent activity.

Results from numerous multicentre studies indicate that individual treatment criteria should be adopted during the maintenance stage, allowing an effective approach to maintaining visual gains, as well as allowing follow-up in clinical practice, with maximum systemic and ocular safety.

Vision is expected to be maintained in 90-95% of patients; a minimum gain of 3 lines should be observed in 30-40% of patients treated with ranibizumab.

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Aflibercept (Eylea®)

Aflibercept is a recombinant fusion protein consisting of the natural (all human) extracellular ligand binding sequences of VEGFR1 and VEGFR2 attached to the Fc portion of an IgG molecule. Aflibercept is approved for the treatment of nAMD, DMO and macular oedema due to RVO.

The three-dimensional configuration of aflibercept enables it to simultaneously bind both sides of the VEGF dimer in a “two-fisted grasp”. This results in a higher binding affinity for VEGF_{165} compared to ranibizumab and bevacizumab, which confers the advantage of the potential for less frequent dosing of aflibercept, with substantial saving in cost and treatment burden to patients. Peak efficacy of aflibercept in patients with nAMD is similar to that of ranibizumab but the duration of action is slightly longer.
Diabetic Macular Oedema

CRT > 400μm

Ranibizumab / Aflibercept
Months 0,1,2 / 0,1,2,3,4,6,8,10

Responsive
Continue until no further improvement in CRT / VA

If new IRF / SRF recommence tx

Insufficient response
(decrease of CRT <100μm or <20%)

Switch anti-VEGF (min of 2 inj)

If no response
see in VKRT clinic

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
Retinal vein occlusion with macular oedema

Ranibizumab / Aflibercept
0, 1, 2 months

Responsive

Continue until no further improvement in CRT / VA

If new IRF / SRF recommence tx

Insufficient response
(decrease of CRT<100μm or <20%)

Switch anti-VEGF
(min of 2 inj)

Responsive

Continue until no further improvement in CRT / VA

If new IRF / SRF recommence tx

Insufficient response

See in VKRVO clinic

Presence of NVI, NVA, NVD, NVE

Urgent PRT +/- anti-VEGF

Urgent appointment in VKRVO clinic / speak with Consultant on the day

DEX Implant*
(if not suitable for anti-VEGF (recent <3/12 or high risk of stroke / MI)

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21
After shadowing the medical retina consultants in clinic for a period of four weeks, the non-medical practitioner will start assessing patients independently but under supervision, discussing a number of 20 cases with the Consultant trainer. Each patient discussed will be recorded in the portfolio and once the non-medical Practitioner has been assessed as competent by the supervisor then he/she will proceed assessing patients unsupervised. A consultant trainer or another responsible doctor will be available at all times for any doubts concerning clinical decisions.

In the following page the assessment appendix.
<table>
<thead>
<tr>
<th>Competence category</th>
<th>Positive features</th>
<th>Opportunities for improvement</th>
<th>Performance level / score</th>
</tr>
</thead>
</table>
| Communication and working with the patient and / or family | - Explanation of procedure to patient and ensuring patient  
- Ongoing reassurance to patient  
- Explanation of main aspects of retinal condition and management options |                                                                              |                                                                                           |                              |
| Safety                                                   | - Checking patient identification on notes and computer database                                                                                                            |                                                                                           |                              |
| Procedural competence                                   | - Assess features of Optical Coherence Tomography (OCT)  
- Decide about appropriate management based on current and previous OCT images, visual acuity results and previous notes  
- Record outcomes on the patients’ notes  
- Fill-in appropriate forms for treatment / clinic review  
- Appropriately seek for advice when in doubt | - Read relevant literature (book / online sources)                                                                                                                        |                                                                                           |                              |
| Team working                                             |                                                                                                                                                                                                                                                                                    |                                                                                           |                              |

Assessors Recording Form

Trainee’s name:                      Date:

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board                  Date: 21/06/19          Review date: 21/06/21
## Assessment Practice Log

<table>
<thead>
<tr>
<th>Date</th>
<th>Assessor’s name</th>
<th>Assessor’s signature</th>
<th>Your signature</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Communication and working with the patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Checking patient identification on notes and computer database</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assess features of Optical Coherence Tomography (OCT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decide about appropriate management</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Record outcomes on the patients’ notes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fill-in appropriate forms for treatment / clinic review</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Title: UHL Intravitreal Injections of Anti-VEGF Medication for Macular Diseases by Non-Medical Practitioners (s) Standard Operating Procedure (LocSSIPs)

Authors: Rossella Anzidei & Vasileios Konidaris

Approved by MSS Board Date: 21/06/19 Review date: 21/06/21